Chandra Ramanathan, executive-in-residence at Mass General Brigham and a biopharmaceutical executive with extensive experience translating scientific ideas into treatment options and access for patients with high medical needs, has joined McLean Hospital’s Board of Trustees.
Ramanathan cited his passion for and expertise in speeding innovations to positively impact patient care, along with McLean’s reputation as an outstanding institution, as reasons for his involvement.
“This is such a promising time for clinical innovation, particularly addressing huge unmet need in mental health,” Ramanathan said. “There is tremendous opportunity to couple the advances in our understanding of the complexity of the brain with digital tools, which can lead to transformative options in neuropsychiatry and patient care.”
Ramanathan has led several initiatives across pharma, biotech, start-ups, and academia from early-stage discovery programs to launching new products.
“We are thrilled to welcome Chandra to the McLean community. His expertise in translational research, combined with his commitment to improving the lives of people living with psychiatric disorders through the advancement of clinical care informed by research, is going to be invaluable in advancing the McLean mission,” said Scott L. Rauch, MD, president and psychiatrist in chief for McLean.